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ImmunohistochemistrySummary Lymphangioleiomyomatosis (LAM) is a rare progressive cystic lung disease with features of a
low-grade neoplasm. It is primarily caused by mutations in TSC1 or TSC2 genes. Sirolimus, an inhibitor
of mTOR complex 1 (mTORC1), slows down disease progression in some, but not all patients. Hitherto,
other potential therapeutic targets such as mTOR complex 2 (mTORC2) and various metabolic pathways
have not been investigated in human LAM tissues. The aim of this study was to assess activities of
mTORC1, mTORC2 and various metabolic pathways in human LAM tissues through analysis of protein
expression. Immunohistochemical analysis of p-S6 (mTORC1 downstream protein), Rictor (mTORC2 scaf-
fold protein) as well as GLUT1, GAPDH, ATPB, GLS, MCT1, ACSS2 and CPT1A (metabolic pathway
markers) were performed on lung tissue from 11 patients with sporadic LAM. Immunoreactivity was
assessed in LAM cells with bronchial smooth muscle cells as controls. Expression of p-S6, Rictor, GAPDH,
GLS, MCT1, ACSS2 and CPT1A was signiﬁcantly higher in LAM cells than in bronchial smooth muscle
cells (P b .01). No signiﬁcant differences were found between LAMcells and normal bronchial smoothmus-
cle cells in GLUT1 and ATPB expression. The results are uniquely derived from human tissue and indicate
that, in addition to mTORC1, mTORC2 may also play an important role in the pathobiology of LAM.Abbreviations: ACSS2, acyl-coenzyme A synthetase short-chain family member 2; ATPB, β-F1-ATPase; BSM, bronchial smooth muscle;
PT1A, carnitine palmitoyltransferase 1A; ER, estrogen receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GLS, glutaminase;
LUT1, glucose transporter 1; HMB-45, homatropinemethylbromide-45; LAM, lymphangioleiomyomatosis;MCT1, monocarboxylate transporter
; mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; p-S6, phosphorylated ribosomal S6 protein;
ictor, rapamycin-insensitive companion of mammalian target of rapamycin; SMA, smooth muscle actin; TSC2, tuberous sclerosis 2 (tuberin).
☆ Disclosures/Conﬂict of Interest: none.
☆☆ Funding/Support: This work was supported by the ÚNKP-17-3 New National Excellence Program of The Ministry of Human Capacities (I. K.), scientiﬁc
rant of the Hungarian Respiratory Foundation (I. K.), Bolyai Fellowship of Hungarian Academy of Sciences (A. S.), and Semmelweis University Innovation Found
TIA-KF-17 (A. S.).
⁎ Corresponding author at: Department of Laboratory Medicine & Pathology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224.
E-mail address: khoor.andras@mayo.edu (A. Khoor).
1 These authors contributed equally to this work.
ttps://doi.org/10.1016/j.humpath.2018.05.018
046-8177/© 2018 Elsevier Inc. All rights reserved.
200 I. Krencz et al.Furthermore, glutaminolysis, acetate utilization and fatty acid β-oxidation appear to be the preferred bioen-
ergetic pathways in LAM cells. mTORC2 and these preferred bioenergetic pathways appear worthy of fur-
ther study as they may represent possible therapeutic targets in the treatment of LAM.
© 2018 Elsevier Inc. All rights reserved.1. Introduction
Lymphangioleiomyomatosis (LAM) is a rare multisystem
disorder with a strong female predilection, manifesting primar-
ily as a progressive, diffuse cystic lung disease. Symptoms are
generally due to obstructive lung disease; however, pleural
complications such as pneumothorax and chylothorax may
also occur. The lung cysts are related to proliferation of imma-
ture smooth muscle cells of perivascular phenotype (LAM
cells) [1] and LAM is now considered as a low-grade neo-
plasm of the perivascular epithelioid cell tumor family [2].
The term sporadic LAM is used for patients without the tuber-
ous sclerosis complex (TSC), while TSC-LAM refers to LAM
that occurs in the setting of TSC. Both forms are primarily
caused by TSC1 or TSC2 gene mutations [3]. These mutations
lead to hyperactivation of the mammalian target of rapamycin
(mTOR) and subsequently proliferation of LAM cells [4].
mTOR is a component of two multiprotein complexes:
mTOR complex 1 and mTOR complex 2 (mTORC1 and
mTORC2) (Fig. 1). In addition to mTOR, mTORC1 contains
scaffold protein Raptor and mTORC2 contains scaffold pro-
tein Rictor [5]. Through its participation in mTORC1 and
mTORC2, mTOR integrates a variety of environmental sig-
nals and regulates cell growth and homeostasis [6]. Activation
of mTORC1 leads to phosphorylation of eukaryotic initiation
factor 4E-binding protein 1 (4EBP1), S6 kinase (S6K), and ri-
bosomal S6 protein. Phospho-S6 (p-S6) facilitates protein
translation, cell growth, and proliferation. mTORC1 also in-
ﬂuences cellular metabolism (Fig. 1). Alternatively, mTORC2
is a mediator of actin cytoskeletal organization and promotes
cell survival via phosphorylation of protein kinase B and se-
rum- and glucocorticoid-induced protein kinase [5, 6].
mTOR also plays a central role in metabolic reprogram-
ming of neoplastic cells with altered utilization of glucose, glu-
tamine, and lipids [5-9]. Increased glucose uptake and
overexpression of glucose transporter 1 (GLUT1) is well doc-
umented in most neoplasms [10, 11]. Regardless, certain neo-
plasms, including LAM, are undetectable by positron emission
tomography using 2-deoxy-2-[18F]ﬂuoro-D-glucose [12-14],
suggesting that these neoplasms may use an alternative energy
source such as glutamine or acetate instead of glucose.
Sirolimus is an mTORC1 inhibitor, which has been suc-
cessfully utilized to attenuate disease progression in LAM pa-
tients [15, 16]. Unfortunately, lost lung function is not restored
and disease progression resumes once treatment is discontin-
ued [16]. In addition, certain disease subgroups, such as those
that are post-menopausal, may have limited if any beneﬁt fromsirolimus. Lastly, the most effective dose and treatment dura-
tion are unknown, although presumed to be lifelong. Of
course, some patients are unable to tolerate the treatment due
to adverse events [17, 18]. It is therefore important to identify
pathobiological targets that may respond to new or additional
therapeutics to mitigate the proliferation of LAM cells.
The purpose of this study was to assess the signiﬁcance of
mTORC1, mTORC2 and various metabolic pathways (includ-
ing glycolysis, oxidative phosphorylation, glutaminolysis,
fatty acid β-oxidation, and acetate utilization) in the pathogen-
esis of LAM, using semiquantitative immunohistochemical
methods on formalin-ﬁxed parafﬁn-embedded human lung
tissue.2. Materials and methods
2.1. Tissues
Our study was approved by the Mayo Clinic Institutional
Review Board. Formalin-ﬁxed parafﬁn-embedded lung tissue
was available from the lung tissue registry for 11 patients with
sporadic LAM. These patients underwent lung transplantation
(7 patients) and diagnostic wedge biopsies (4 patients) atMayo
Clinic in Jacksonville, Florida, between January 1, 2004 and
December 31, 2016. Diagnosis of LAMwas based on the pres-
ence of characteristic clinical, radiologic, and histologic ﬁnd-
ings and was conﬁrmed by immunoreactivity for smooth
muscle actin (SMA), HMB-45 and β-catenin. Clinical and
pathologic parameters are summarized in Table 1. Two pa-
tients (patient no. 6 and 8) received hormone therapy and none
of the patients received mTOR inhibitor therapy prior to
surgery.2.2. Immunohistochemistry
Representative tissue blocks were selected for each patient
by a pulmonary pathologist (AK). Immunohistochemistry was
performed on 4 μm-thick sections of formalin-ﬁxed parafﬁn-
embedded tissue. After deparafﬁnization and endogenous per-
oxidase blocking, antigen retrieval was performed for 20 to 30
minutes (buffers: 10 mM citrate pH 6.0; 10 mM Tris-EDTA
pH 9.0; cell conditioning 1 antigen retrieval buffer pH 8.5
[Ventana Medical Systems, Inc.]; Target Retrieval Solution
buffer pH 9.0 [Dako]). Slides were incubated with the diluted
primary antibodies summarized in Table 2. mTORC1 activity
Fig. 1 Simpliﬁed scheme of studied PI3K/Akt/mTOR and bioenergetic pathways.Proteins analyzed by immunohistochemistry are shown in red.
LAM cells have an aberrant activation of mTOR caused by mutations in TSC1 or TSC2 genes. mTOR protein kinase is present in 2 multiprotein
complexes, mTORC1 and mTORC2, which are characterized by different scaffold proteins, Raptor and Rictor, respectively. Activation of
mTORC1 enhances protein translation and cell growth and proliferation via phosphorylation of eukaryotic initiation factor 4E-binding protein
and activation S6 kinase (S6K). Activation of S6K leads to phosphorylation of S6 ribosomal protein. In contrast, mTORC2 is a mediator of actin
cytoskeletal organization and promotes cell survival. mTOR complexes have a central role inmetabolic regulation, including utilization of glucose,
glutamine, acetate, and lipids. According to recent studies [8,32], activation of mTORC1 can stimulate glycolysis and glutaminolysis (solid blue
lines). In LAMcells, a correlation betweenmTORC1 activity and glutaminolysis was detected. A strong positive correlation between expression of
Rictor and ACSS2 was also detected in our study, which suggests that mTORC2 may inﬂuence utilization of acetate (dashed blue line).
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pho-S6 (p-S6). In the absence of a strong antibody for a down-
stream protein, mTORC2 activity was estimated by expression
of mTORC2 associated protein Rictor. Glycolysis and oxida-
tive phosphorylation were characterized by GLUT1, glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) and β-F1-
ATPase (ATPB), glutaminolysis by glutaminase (GLS), fatty
acid β-oxidation by carnitine palmitoyltransferase 1A
(CPT1A), and acetate utilization by acyl-coenzyme A synthe-
tase short-chain family member 2 (ACSS2) and monocarbox-
ylate transporter 1 (MCT1). Expression of LAM cell markersSMA, HMB-45 and β-catenin) and hormone receptors (estro-
gen and progesterone) was also examined. Immunohistochem-
ical reactions were visualized by Novolink Polymer (Leica
Biosystems) and VECTASTAIN Universal (Vector Laborato-
ries) detection systems, using 3,3′-diaminobenzidine as chro-
mogen (Fig. 2).
Immunostained sections were reviewed by 2 pathologists
(I.K. and J.P.) with a focus on immunoreactivity for lesional
LAM cells. As a minimum, three LAM nodules containing
at least 100 cells per nodule were examined in each case. There
is no proven precursor for the LAM cell; therefore, we used
Table 1 Clinicopathologic characteristics of LAM patients
Patient Age
(years)
Dx-Bx
time (years)
Procedure Lymph
node
metastasis
Smoking
history
VEGF-D
(pg/mL)
Treatment before procedure
Hormone therapy mTOR inhibitor
1 59 0 Wedge biopsy Unknown Never Not done No No
2 39 1 BLT Yes Former smoker Not done No No
3 41 1 BLT No Former smoker Not done No No
4 35 5 BLT No Never Not done No No
5 37 5 BLT Yes Former smoker Not done No No
6 39 3 BLT Yes Never Not done Yes No
7 58 2 BLT Yes Never Not done No No
8 49 11 BLT No Former smoker Not done Yes No
9 34 0 Excision of bleb Unknown Never Not done No No
10 43 0 Wedge biopsy Unknown Never 385 No No
11 32 0 Wedge biopsy Unknown Never 8888 No No
Abbreviations: BLT, bilateral lung transplantation; Bx, biopsy; Dx, diagnosis, mTOR, mammalian target of rapamycin; VEGF-D, vascular endothelial growth
factor D.
202 I. Krencz et al.bronchial smooth muscle (BSM) cells as an internal control.
Comparison to BSM is consistent with the smooth muscle hy-
pothesis of LAM cell derivation and the fact that both BSMTable 2 Primary antibodies and their conditions used in this study
Antibody Antigen Clone Dilution Antigen
retrieval
Cellu
LAM markers
β-
Catenin
17C2 1:100
Tris-EDTA
(pH 9)
Memb
cytopla
HMB-
45
HMB-45 Predilute TRS (pH 9) Cytopl
SMA 1A4 1:400 Citrate (pH 6) Cytopl
Hormone
receptors
ER SP1 Predilute CC1 (pH 8.5) Nuclea
PR 1E2 Predilute CC1 (pH 8.5) Nuclea
mTOR
markers
p-S6 #2211 1:100 Citrate (pH 6) Cytopl
Rictor A500-
002A
1:1000 Citrate (pH 6) Cytopl
Metabolic
markers
GLUT1 ab652 1:400 Citrate (pH 6)
Memb
cytopla
GAPDH ab8245 1:600 Citrate (pH 6) Cytopl
nuclea
ATPB ab14730 1:100 Citrate (pH 6) Cytopl
GLS ab156876 1:200 Citrate (pH 6) Cytopl
MCT1 A304-
358A
1:100 Citrate (pH 6) Memb
cytopla
ACSS2 #3658 1:200 Citrate (pH 6) Cytopl
nuclea
CPT1A ab128568 1:500 Citrate (pH 6) Cytopl
Abbreviations: ACSS2, acyl-coenzyme A synthetase short-chain family member 2
toyltransferase 1A; ER, estrogen receptor; GAPDH, glyceraldehyde 3-phosphate d
homatropine methylbromide 45; LAM, lymphangioleiomyomatosis; MCT1, mono
mammalian target of rapamycin complex; PR, progesterone receptor; p-S6, phosph
mammalian target of rapamycin; SMA, smooth muscle actin.cells and LAM cells are strongly positive for SMA (see Fig.
2.). Immunohistochemical expression ofmTOR andmetabolic
markers was also analyzed in vascular smooth muscle cells inlar localization Signiﬁcance Supplier
ranous and
smic
LAM marker
Novocastra Laboratories
Ltd
asmic LAM marker Dako
asmic LAM marker Dako
r ER status
Ventana Medical
Systems, Inc
r PR status Ventana Medical
Systems, Inc
asmic mTORC1
Cell Signaling
Technology, Inc
asmic mTORC2 Bethyl Laboratories, Inc
ranous and
smic
Glucose uptake Abcam
asmic and
r
Glycolysis Abcam
asmic Oxidative
phosphorylation
Abcam
asmic Glutaminolysis Abcam
ranous and
smic
Lactate and acetate
uptake
Bethyl Laboratories, Inc
asmic and
r
Acetate consumption Cell Signaling
Technology, Inc
asmic β-oxidation of fatty
acids
Abcam
; ATPB, β-F1-ATPase; CC1, cell conditioning 1; CPT1A, carnitine palmi-
ehydrogenase; GLS, glutaminase; GLUT1, glucose transporter 1; HMB-45,
carboxylate transporter 1; mTOR, mammalian target of rapamycin; mTORC,
orylated ribosomal S6 protein; Rictor, rapamycin-insensitive companion of
Fig. 2 Immunohistochemical stainings in LAM and BSM cells (patient no. 2) for LAM markers (β-catenin, HMB-45, SMA), hormone recep-
tors (ER, PR), mTORC1/C2 markers (p-S6, Rictor), and metabolic markers (GLUT1, GAPDH, ATPB, GLS, MCT1, ACSS2, CPT1A).Original
magniﬁcation ×200. BSM cells are indicated with asterisks (*).
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identical to that in BSM cells (data not shown). For mTOR and
metabolic markers, an H-score was calculated by multiplying
the fraction of immunopositive LAM cells (%) by staining in-
tensity (0, 1+, 2+ or 3+), as previously described [19]. For ex-
ample, 50% of LAM cells staining positive with 3+ intensity
results in an H-score of 150. Based on the H-score, immuno-
histochemical expression of these markers was categorized
as follows: no expression (H-score ≤ 10), low expression
(H-score 11–100), and high expression (H-scoreN 100). For
SMA, HMB-45 and β-catenin, any staining was considered
positive. For estrogen and progesterone receptors, the percent-
age of positive cells was recorded.
2.3. Statistical analysis
Statistical analysis was performed using IBM SPSS Sta-
tistics software, version 22 (SPSS Inc.). The Wilcoxon
signed rank test was used to evaluate the differences be-
tween LAM cells and matched normal BSM cells. The
Mann–Whitney test and Spearman rank correlation wereused to compare protein expressions and clinicopathologic
parameters. A 2-tailed test was used to calculate statistical
signiﬁcance. To achieve highly reliable results, signiﬁcance
was deﬁned as P ≤ .01.3. Results
3.1. Expression of LAM cell markers
Expression of LAM cell markers and hormone receptors
are shown in Table 3. LAM cells were positive for HMB-45
in 9 of 11 cases (82%). All cases were positive for SMA and
β-catenin.
3.2. Expression of mTOR-related proteins
In LAM cells, high p-S6 expression suggesting high
mTORC1 activity was observed in 10 of 11 cases (91%),
and high Rictor expression suggesting high mTORC2 activity
Table 3 Expressions of LAM markers (HMB-45, β-catenin, SMA) and hormone receptors (ER, PR) in LAM cells
Patient HMB-45 β-Catenin SMA ER (%) PR (%)
1 Positive Positive Positive 50 10
2 Positive Positive Positive 60 40
3 Negative Positive Positive 0 60
4 Positive Positive Positive 50 20
5 Positive Positive Positive 40 70
6 Positive Positive Positive 50 30
7 Positive Positive Positive 60 30
8 Positive Positive Positive 70 20
9 Positive Positive Positive 70 60
10 Negative Positive Positive – –
11 Positive Positive Positive 75 60
Abbreviations: ER, estrogen receptor; HMB-45, homatropine methylbromide 45; LAM, lymphangioleiomyomatosis; PR, progesterone receptor; SMA, smooth
muscle actin.
204 I. Krencz et al.was observed in 6 of 11 cases (55%) (Fig. 3). Low expression
for both p-S6 and Rictor was observed in only 1 case. In con-
trast, no or low expression was observed in BSM cells for both
of these markers in all cases. The difference between LAMand
BSM cells was statistically signiﬁcant for both p-S6 and Rictor
(P b .01) (Fig. 4).
3.3. Expression of metabolic pathway–related
proteins
3.3.1. Glycolysis and oxidative phosphorylation
Membranous or cytoplasmic immunoreactivity for GLUT1
(marker for glucose uptake) was detectable in LAM cells in 5
of 11 cases (45%), the expression was low in 4 cases and high
in 1 (Fig. 3). Minimal or no GLUT1 expression was observed
in normal BSM cells in all cases; however, the difference in H-
scores between LAM and BSM cells was not statistically sig-
niﬁcant (P = .61) (Fig. 4).Fig. 3 H-scores for p-S6, Rictor, GLUT1, GAPDH, ATPB, GLS, MC
tochemical expression was categorized as follows: no expression (H-scor
scoreN 100).Cytoplasmic immunoreactivity was evaluated for GAPDH
(marker for glycolysis) and ATPB (marker for oxidative phos-
phorylation). In LAM cells, high expression of cytoplasmic
GAPDH was detected in 7 cases (64%) and high expression
of ATPB was detected in 4 (36%) (Fig. 3). On the other hand,
BSM cells showed high expression of ATPB in only 1 case
(9%) and high expression of GAPDH in none. The difference
in H-scores between LAM and BSM cells was statistically sig-
niﬁcant for GAPDH (P b .01), but not for ATPB (P = .02)
(Fig. 4).
3.3.2. Glutaminolysis
GLS (marker of glutaminolysis) was expressed in LAM
cells in 10 of 11 cases (91%); in 7 cases (64%) the expression
was high (Fig. 3). On the other hand, GLS expression was ei-
ther low (1 case [9%]) or absent (10 cases [91%]) in BSM
cells. The H-score for GLS was signiﬁcantly higher in LAM
cells compared to BSM cells (P b .01) (Fig. 4).T1, ACSS2, and CPT1A in all patients in LAM Cells.Immunohis-
e ≤ 10), low expression (H-score 11–100), and high expression (H-
* *
* *
* * *
Fig. 4 Expression levels of mTOR and metabolic markers in LAM cells and BSM cells.H-scores of p-S6, Rictor, GAPDH, GLS, MCT1,
ACSS2, and CPT1A were signiﬁcantly higher in LAM cells than in BSM cells. In contrast, H-scores of GLUT1 and ATPB were not statistically
different between LAM and BSM cells. *P ≤ .01 calculated with Wilcoxon signed rank test.
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Expression of CPT1A (rate-limiting enzyme in fatty acid
β-oxidation) was high in both LAM and BSM cells in all cases
(Fig. 3). Nevertheless, the mean H-score for CPT1A was sig-
niﬁcantly higher in LAM cells than in BSM cells (P b .01)
(Fig. 4).
3.3.4. Acetate uptake and utilization
Expressions of MCT1 (transporter for monocarboxylates,
eg, lactate and acetate) and ACSS2 (marker for the possibility
of cellular acetate utilization) were high in LAM cells in 7
(64%) and 9 (82%) cases, respectively (Fig. 3). On the otherhand, MCT1 and ACSS2 expressions were low or absent in
BSM cells in all cases. The H-score was signiﬁcantly higher
in LAM cells than in BSM cells for both MCT1 and ACSS2
(P b .01) (Fig. 4).
3.4. Correlation between mTOR and metabolic path-
way–related proteins
The association between expression of p-S6 and Rictor and
that of metabolic pathway–related proteins was also studied.
In LAM cells, positive correlation was detected between p-
S6 and GLS (r = 0.732, P = .01) and between Rictor and
206 I. Krencz et al.ACSS2 (r = 0.849, P b .01). In addition, positive correlation
was observed between Rictor and ACSS2 in BSM cells (r =
0.769, P b .01).
3.5. Correlation between protein expression and
clinicopathologic parameters
The H-score for both Rictor and ATPB appeared to be
higher in explanted (end-stage) lungs than diagnostic wedge
biopsies, but results were not statistically signiﬁcant at P ≤
.01. Positive correlation was also observed between H-scores
for CPT1A and estrogen receptor (ER) positivity (r = 0.808,
P b .01). No other association was observed between protein
expression and clinicopathologic parameters.4. Discussion
Histologically, LAM is characterized by cystic spaces sur-
rounded by bundles of proliferating LAM-type smooth muscle
cells [20]. These LAM cells are typically immunoreactive for
HMB-45, β-catenin, SMA, desmin, ER, and progesterone re-
ceptor [21-24].
mTOR plays an important role in the regulation of protein
translation, cell growth, proliferation, cytoskeletal organiza-
tion, and cellular metabolism [5, 8, 9] (Fig. 1). In this study,
expression of p-S6 (downstream target of mTORC1) and Ric-
tor (part of mTORC2) was used to estimate mTORC1 and
mTORC2 activity, respectively. Findings suggested high
mTORC1 and mTORC2 activity in LAM cells in 91% and
55% of the cases, respectively. High mTORC1 activity in
LAM cells is consistent with previous observations [19, 25].
Our ﬁndings suggest that high mTORC2 activity may also
play a role in the pathobiology of LAM.
To our knowledge, our study was the ﬁrst to investigate
mTOR-related bioenergetic pathways, including glycolysis,
oxidative phosphorylation, glutaminolysis, fatty-acid β-ox-
idation, and acetate utilization in human LAM tissue. High
expression of GLS, CPT1A, MCT1, and ACSS2 in our
study suggests that glutaminolysis, fatty acid β-oxidation,
and acetate utilization may play important roles in LAM cell
metabolism. An important role for glutaminolysis has also
been shown in TSC2-deﬁcient mouse embryonic ﬁbroblast
cells, which are used as an in vitro model for LAM [26,
27]. Some tumors become dependent on acetate or lipids for
their growth and survival [28, 29]. Our observation on
MCT1, ACSS2, and CPT1A suggests that LAM may be one
of these tumors. Moreover, association between CPT1A and
ER expression indicates that ERs may affect the lipid metabo-
lism as it has been previously described in breast and endome-
trial cancer [30, 31].
No statistically signiﬁcant differences were found between
LAM cells and normal BSM cells in GLUT1 and ATPB ex-
pression, suggesting that glucose uptake and oxidative phos-
phorylation are at a relatively low level in LAM cells. Thelow glucose uptake in our study is consistent with the clinical
assessment by lung positron emission tomography scans, that
demonstrated low 2-deoxy-2-[18F]ﬂuoro-D-glucose uptake
in LAM [14].
Targeting mTOR and various bioenergetic pathways can
play an important role in individualized therapy of neoplasms
[6-9, 28]. Sirolimus, an mTORC1 inhibitor, has been utilized
successfully to attenuate disease progression in patients with
LAM [16]; however, there are limitations to the treatment ef-
fect as noted in the introduction [17, 18]. Our ﬁndings of high
mTORC1 and mTORC2 activities in the majority of LAM
cases suggest that dual mTORC1/mTORC2 inhibitors may
be worthy of clinical investigation, especially in cases with
high mTORC2 activity. These cases may be identiﬁed by im-
munohistochemistry for Rictor.
In our study, expression of p-S6 (mTORC1) correlatedwith
that of GLS (glutaminolysis) and expression of Rictor
(mTORC2) correlated with that of ACSS2 (acetate utilization)
in LAM cells. The former observation is in agreement with re-
cent studies showing that mTORC1 promotes glutamine me-
tabolism [8, 32, 33]. Correlation between mTORC1 and
glutaminolysis and mTORC2 and acetate utilization suggests
that inhibitors that block mTORC1 and mTORC2 may also
have therapeutic effects by blocking glutaminolysis and ace-
tate utilization, which appear to be main sources of LAM cell
metabolism. Some LAM-related bioenergetic pathways re-
vealed by our study (eg, acetate utilization) may also represent
a promising opportunity for the development of new agents in
treatment of LAM.
Interestingly, a relatively low level of hormonal cell surface
activity was seen and may partially explain the variable clini-
cal response to changes in either endogenous or exogenous
levels. For example, not all patients worsen during pregnancy
and there is little improvement with traditional methods of es-
trogen suppression [34]. Hormonal manipulation may be rele-
gated to an adjunctive role requiring additional study [35].
Our study has some limitations. Although the antibodies
used in this study are widely accepted markers of mTOR
and metabolic pathways, correlation between immunohisto-
chemical overexpression of proteins and pathway activities
requires further investigation. Also, our results are limited
to identiﬁcation of abnormalities without the ability to dis-
tinguish cause and effect. Furthermore, hypoxia impacts
cellular respiration and, therefore, may play a role in the di-
version from aerobic handling of pyruvate to fatty acid me-
tabolism, acetate utilization, and glutaminolysis. Finally,
the results indicate potential targets for therapy, but it is un-
known whether interventions would result in a clinically
meaningful outcome.
In summary, this is the ﬁrst study to analyze expression
of mTORC1, mTORC2 and a set of bioenergetic pathway
markers in human lung tissue affected by LAM. If clinically
validated, the immunohistochemical panel we have devel-
oped may potentially guide clinical interventional trials of
new or additional therapeutics for patients suffering from
LAM.
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